



## Maertens et al Divisional of Serial No. 08/362,455

- 26. (new) An HCV antibody according to claims 24 or 25 being a monoclonal antibody
  - 27. (new) An HCV antibody according to claim 24, further comprising a label.
  - 28. (new) An HCV antibody according to claim 25, further comprising a label.
  - 29. (new) An HCV antibody according to claim 26, further comprising a label.
- 30. (new) An HCV antibody according to claims 27 wherein said label is of the enzymatic, fluorescent or radioactive type.
- 31. (new) An HCV antibody according to claims 28 wherein said label is of the enzymatic, fluorescent or radioactive type.
- 32. (new) An HCV antibody according to claims 29 wherein said label is of the enzymatic, fluorescent or radioactive type.
- 33. (new) An HCV antibody according to any of claims 24-25 further being humanized by means of recombinant DNA technology.
- 34. (new) An HCV antibody according to any of claim 26 further being humanized by means of recombinant DNA technology.
- 35. (new) A kit for determining the presence of HCV antigens present in a biological sample, comprising,
- (a) at least one monoclonal antibody according to any of claims 24-25 or 27-30,
  - (b) a buffer or components necessary or producing the buffer enabling the binding reaction between these antibodies and the HCV antigens present in said biological sample,





## Maertens et al Divisional of Serial No. 08/362,455

- (c) a means for detecting the immune complexes formed in the preceding binding reaction.
- 36. (new) A kit for determining the presence of HCV antigens present in a biological sample, comprising,
  - (a) at least one monoclonal antibody according to any of claim 26,
- (b) a buffer or components necessary or producing the buffer enabling the binding reaction between these antibodies and the HCV antigens present in said biological sample,
- (c) a means for detecting the immune complexes formed in the preceding binding reaction.
- 37. (new) A kit for determining the presence of HCV antigens present in a biological sample, comprising,
  - (a) at least one monoclonal antibody according to any of claim 33,
- (b) a buffer or components necessary or producing the buffer enabling the binding reaction between these antibodies and the HCV antigens present in said biological sample,
- (c) a means for detecting the immune complexes formed in the preceding binding reaction.
- 38. (new) A humanized version of an HCV antibody according to any of claims 24-25 or 27-30.
- 39. (new) A humanized version of an HCV antibody according to any of claim 26.